Security
bioAffinity Technologies, Inc. Warrant · BIAFW
BIAFWNASDAQWarrantCurrentCIK 1712762Updated Nov 9, 2026
Name history
bioAffinity Technologies, Inc. · through Nov 6, 2026
BIAFW price & chart
Loading TradingView…
NASDAQ:BIAFW on TradingView ↗About the company
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
In the news
No coverage from other publishers is available.
Seeking Alpha
bioAffinity Technologies, Inc. (BIAF) Discusses Noninvasive Testing and Risk Stratification for Indeterminate Lung Nodules Transcript ↗
bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis Transcript ↗
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
424B5 filing
424B5 filing
Other Events
Items 8.01, 9.01
Show 5 more recent filings
DEF 14A filing
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
PRER14A filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other Events
Items 1.01, 3.02, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 11,546,369Source | 6,552,014Source | 7,619,279Source | 4,751,075Source | 6,656,448Source | 7,945,252Source | 5,547,283Source | 8,049,266Source | 10,960,772Source | 6,513,667Source | 8,221,552Source | 12,182,125Source |
| Property, Plant and Equipment, NetUSD | 303,122Source | 418,190Source | 313,708Source | 351,368Source | 449,250Source | 246,849Source | 382,409Source | 461,209Source | 265,593Source | 375,385Source | 458,633Source | 214,438Source |
| GoodwillUSD | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 731,389Source | 789,722Source | 687,639Source | 745,972Source | 804,306Source | 702,222Source | 760,556Source | 818,889Source | 716,806Source | 775,139Source | 833,472Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,669,195Source | 756,580Source | 2,429,719Source | 802,835Source | 801,311Source | 3,098,366Source | 444,706Source | 2,453,165Source | 6,449,782Source | 1,105,291Source | 2,821,570Source | 11,413,759Source |
| Inventory, NetUSD | 35,234Source | 25,363Source | 82,378Source | 43,971Source | 29,768Source | 77,887Source | 38,782Source | 9,487Source | 53,548Source | 27,608Source | 18,484Source | 5,540Source |
| Assets, CurrentUSD | 8,613,606Source | 2,549,138Source | 3,865,280Source | 1,668,826Source | 2,680,431Source | 4,341,401Source | 1,863,782Source | 3,931,161Source | 7,565,208Source | 2,695,098Source | 3,972,745Source | 11,961,687Source |
| Prepaid Expense and Other Assets, CurrentUSD | 460,187Source | 440,027Source | 458,360Source | 400,151Source | 253,726Source | 479,913Source | 416,550Source | 344,900Source | 519,916Source | 422,995Source | 321,017Source | 531,899Source |
| Operating Lease, Right-of-Use AssetUSD | 367,398Source | 493,687Source | 769,270Source | 399,879Source | 324,942Source | 651,430Source | 431,746Source | 347,860Source | 334,289Source | 463,011Source | 370,312Source | — |
| Other Assets, NoncurrentUSD | 12,815Source | 19,676Source | 16,709Source | 12,814Source | 19,675Source | 12,816Source | 19,675Source | 16,060Source | 12,815Source | 19,676Source | 16,060Source | 6,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,644,171Source | 3,430,989Source | 3,850,482Source | 6,887,183Source | 3,223,334Source | 4,283,866Source | 4,107,879Source | 2,792,215Source | 3,683,116Source | 3,911,631Source | 3,366,297Source | 1,138,682Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 1Source | — | 1Source | — | — | 1Source | — | — | 1Source | — | — | — |
| Common Stock, Value, IssuedUSD | 24,264Source | 90,064Source | 47,454Source | 5,801,000Source | 79,407Source | 31,464Source | 124,777Source | 78,515Source | 31,461Source | 106,593Source | 65,762Source | 58,669Source |
| Additional Paid in CapitalUSD | 74,294,531Source | 53,708,374Source | 79,272,098Source | 58,032,170Source | 52,030,280Source | 75,814,595Source | 57,619,354Source | 51,744,830Source | 75,800,258Source | 56,139,753Source | 49,393,972Source | 47,652,242Source |
| Retained Earnings (Accumulated Deficit)USD | -65,416,598Source | -50,677,413Source | -75,550,756Source | -60,365,514Source | -48,676,573Source | -72,184,674Source | -56,304,727Source | -46,566,294Source | -68,554,064Source | -53,644,310Source | -44,604,479Source | -36,667,468Source |
| Stockholders' Equity Attributable to ParentUSD | 8,902,198Source | 3,121,025Source | 3,768,797Source | -2,136,108Source | 3,433,114Source | 3,661,386Source | 1,439,404Source | 5,257,051Source | 7,277,656Source | 2,602,036Source | 4,855,255Source | 11,043,443Source |
| Liabilities and EquityUSD | 11,546,369Source | 6,552,014Source | 7,619,279Source | 4,751,075Source | 6,656,448Source | 7,945,252Source | 5,547,283Source | 8,049,266Source | 10,960,772Source | 6,513,667Source | 8,221,552Source | 12,182,125Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,359,573Source | 2,491,164Source | 2,680,906Source | 2,588,304Source | 2,326,288Source | 3,184,960Source | 3,415,409Source | 1,771,590Source | 2,906,166Source | 3,104,905Source | 2,247,829Source | 1,138,682Source |
| Operating Lease, Liability, CurrentUSD | 136,197Source | 124,710Source | 163,276Source | 133,239Source | 98,593Source | 142,303Source | 130,342Source | 96,631Source | 139,220Source | 127,498Source | 94,708Source | — |
| Accounts Payable, CurrentUSD | 940,761Source | 782,937Source | 969,845Source | 1,169,837Source | 848,102Source | 836,211Source | 1,381,578Source | 383,993Source | 761,901Source | 987,311Source | 604,789Source | 345,042Source |
| Operating Lease, Liability, NoncurrentUSD | 238,942Source | 375,139Source | 637,643Source | 274,074Source | 232,714Source | 545,157Source | 308,415Source | 258,110Source | 202,878Source | 342,098Source | 283,001Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 984,547Source | 904,252Source | 1,414,492Source | 1,048,034Source | 969,093Source | 2,033,924Source | 1,370,735Source | 883,319Source | 1,717,989Source | 1,398,722Source | 1,149,811Source | 541,894Source |
| Deferred Revenue, CurrentUSD | 37,915Source | 24,404Source | 31,140Source | 24,404Source | 26,135Source | 31,140Source | 24,404Source | 30,174Source | 42,405Source | 24,404Source | 33,058Source | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 184,998Source | 311,678Source | 137,014Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | 8,600,000Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 14,340Source | 326,616Source | 671,474Source | 989,681Source | 748,823Source | 248,592Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 24,339Source | 11,174Source | 25,940Source | 9,124Source | 12,944Source | 5,540Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 74,310Source | 394,267Source | -225,410Source | 382,521Source | -14,501Source | 114,635Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,227,240Source | -1,641,775Source | -9,328,842Source | -7,264,795Source | -6,037,806Source | -4,070,845Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | — | 2,186,497Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -5,663Source | -50,786Source | -60,568Source | -79,083Source | -2,209,399Source | -219,987Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 5,663Source | 50,786Source | 60,568Source | 79,083Source | 22,902Source | 219,987Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -118,513Source | 1,031,976Source | 14,733,901Source | 5,627,599Source | -344,984Source | 14,343,953Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,351,416Source | -660,585Source | 5,344,491Source | -1,716,279Source | -8,592,189Source | 10,053,121Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 10,026Source | 542Source | 44,042Source | 17,610Source | 37,125Source | 30,637Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | 8,695Source | 23,385Source | 11,650Source | 20,993Source | 2,459Source |
| Additional Financial Items | ||||||||||||
| Accretion ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 2,055,627Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 67,132Source | 185,687Source | — | 211,607Source | 14,340Source | 326,616Source | 671,474Source | 989,681Source | 748,823Source | 248,592,000Source |
| Amortization of Intangible AssetsUSD | — | — | 14,583Source | 14,583Source | — | — | 14,583Source | 14,583Source | 58,334Source | 58,333Source | 16,528Source | — |
| DepreciationUSD | — | — | 44,599Source | 40,472Source | 23,108Source | 44,468Source | 24,408Source | 43,763Source | 170,359Source | 162,332Source | 233,064Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 212,258Source |
| GoodwillUSD | — | — | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | 1,404,486Source | — |
| Income Tax Expense (Benefit)USD | — | — | 3,182Source | 2,559Source | — | 28,984Source | — | 8,695Source | 44,042Source | 11,650Source | 20,993Source | 2,459Source |
| InterestExpenseNonoperatingUSD | — | — | 5,358Source | 21,631Source | 11,688Source | 10,460Source | 14,722Source | 15,485Source | 44,372Source | 92,475Source | — | — |
| Investment Income, InterestUSD | — | — | 1,088Source | 2,228Source | 3,358Source | 2,025Source | 10,026Source | 542Source | 23,385Source | 17,610Source | 122,131Source | 46,708Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,051,084Source | -2,000,840Source | -3,366,082Source | -4,060,787Source | -3,630,610Source | -2,660,417Source | -14,909,754Source | -9,039,831Source | -7,937,011Source | -8,154,113Source |
| Nonoperating Income (Expense)USD | — | — | -2,755,056Source | -24,417Source | -31,218Source | -1,516,243Source | -13,634Source | -24,583Source | -4,293,204Source | -74,736Source | 57,210Source | — |
| Operating ExpensesUSD | — | — | 3,738,912Source | 4,324,250Source | 4,845,443Source | 3,785,043Source | 4,968,503Source | 4,480,736Source | 16,734,467Source | 18,315,467Source | 10,505,727Source | 4,015,394Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 74,899Source | — | 74,900Source |
| Operating Costs and Expenses | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,446,066Source | 2,350,386Source | 1,510,579Source | 1,269,483Source | 1,351,527Source | 1,853,597Source | 6,161,959Source | 9,362,022Source | 7,900,000Source | 4,803Source |
| Cost of Goods and Services Sold | — | — | — | — | — | — | — | — | — | — | — | —Source |
| Selling, General and Administrative ExpenseUSD | — | — | 2,209,441Source | 2,364,592Source | 2,858,590Source | 2,214,561Source | 3,241,602Source | 2,452,549Source | 9,913,729Source | 9,943,473Source | 6,790,654Source | 2,727,071Source |
| Operating Income (Loss)USD | — | — | -2,292,846Source | -1,973,864Source | -3,334,864Source | -2,515,560Source | -3,616,976Source | -2,627,139Source | -10,572,508Source | -8,953,445Source | -7,973,228Source | -4,011,058Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -5,047,902Source | -1,998,281Source | -3,366,082Source | -4,031,803Source | -3,630,610Source | -2,651,722Source | -14,865,712Source | -9,028,181Source | -7,916,018Source | -8,151,654Source |
| Income Tax Expense (Benefit)USD | — | — | 3,182Source | 2,559Source | — | 28,984Source | — | 8,695Source | 44,042Source | 11,650Source | 20,993Source | 2,459Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,051,084Source | -2,000,840Source | -3,366,082Source | -4,060,787Source | -3,630,610Source | -2,660,417Source | -14,909,754Source | -9,039,831Source | -7,937,011Source | -8,154,113Source |
| Earnings Per Share, BasicUSD per share | — | — | -4.74Source | -4.84Source | -0.64Source | -5.07Source | -0.81Source | -4.8Source | -8.66Source | -0.75Source | -0.91Source | -1.81Source |
| Earnings Per Share, DilutedUSD per share | — | — | -4.74Source | -4.84Source | -0.64Source | -5.07Source | -0.81Source | -4.8Source | -8.66Source | -0.75Source | -0.91Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,066,350Source | 412,936Source | 5,226,753Source | 800,637Source | 4,494,752Source | 541,841Source | 1,721,082Source | 12,125,029Source | 8,747,509Source | 4,498,964Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,066,350Source | 412,936Source | 5,226,753Source | 800,637Source | 4,494,752Source | 541,841Source | 1,721,082Source | 12,125,029Source | 8,747,509Source | — |
| Interest Expense (non-operating)USD | — | — | 5,358Source | 21,631Source | 11,688Source | 10,460Source | 14,722Source | 15,485Source | 44,372Source | 92,475Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 14,583Source | 14,583Source | — | — | 14,583Source | 14,583Source | 58,334Source | 58,333Source | 16,528Source | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 44,042Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 113,360Source | 151,298Source | 61,556Source | 113,229Source | 114,518Source | 154,588Source | 504,836Source | 605,637Source | 249,592Source | 10,182Source |
| Gross ProfitUSD | — | — | — | — | — | — | — | — | — | — | — | 4,336Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | — | — | — | — | — | — | — | 0.99Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 37,125Source | 2,532,640Source |
| Investment Income, InterestUSD | — | — | 1,088Source | 2,228Source | 3,358Source | 2,025Source | 10,026Source | 542Source | 23,385Source | 17,610Source | 122,131Source | 46,708Source |
| Nonoperating Income (Expense)USD | — | — | -2,755,056Source | -24,417Source | -31,218Source | -1,516,243Source | -13,634Source | -24,583Source | -4,293,204Source | -74,736Source | 57,210Source | — |
| Operating ExpensesUSD | — | — | 3,738,912Source | 4,324,250Source | 4,845,443Source | 3,785,043Source | 4,968,503Source | 4,480,736Source | 16,734,467Source | 18,315,467Source | 10,505,727Source | 4,015,394Source |
| Research and Development ExpenseUSD | — | — | 330,589Source | 274,497Source | 361,575Source | 311,372Source | 349,707Source | 367,386Source | 1,383,359Source | 1,461,227Source | 1,467,936Source | 1,142,777Source |
| Operating Costs and Expenses | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-298597
Registration 333-296764
- Gross proceeds
- 120000.0
- Net proceeds
- 2961554.0
- Deal price
- 0.8
- Shares
- 150000
- Offering amount
- $120,000.
- Offering price
- $0.80
- Ticker
- BIAF
Underwriters: WallachBeth Capital LLC
Registration 333-295465
Registration 333-290480
- Gross proceeds
- 4798284.03
- Net proceeds
- 4414421.31
- Deal price
- 2.5
- Shares
- 1919314
- Offering price
- $2.50
- Ticker
- BIAF
Registration 333-289944
Registration 333-286921
- Gross proceeds
- 3233400.58
- Net proceeds
- 2974728.54
- Deal price
- 0.32
- Shares
- 10104377
- Offering price
- $0.32
- Ticker
- BIAF
Registration 333-286497
Filing attachments
ex99-1.htm · 8-K · 2026-11-06
Exhibit 99.1 News Release bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization CyPath® Lung test unit sales double year to date over 2025, with solid gains in physician utilization and recurring orders; testing revenue increases 79% year-to-date Company advances precision medicine pipeline with new asthma and COPD research, collaboration with Pictor and continued development of topical skin cancer therapeutics SAN ANTONIO, Te…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-29
Exhibit 99.1 News Release bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month Benefits of CyPath® Lung to be shared with North Carolina patient advocacy and healthcare community at November 5 “Battle of the Blues” Event SAN ANTONIO, Texas - October 29, 2026 - In recognition of National Lung Cancer Awareness Month, bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology …
Read attachment ↗ex99-1.htm · 8-K · 2026-10-15
Exhibit 99.1 News Release bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026 Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung Presentation to address current challenges in pulmonary nodule management and to discuss preliminary research data from the ongoing development of a new, investigational test for asthma and COPD bioAffinity Technologies’ Medical and Scienti…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-13
Exhibit 99.1 News Release bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026 Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targets Company advances research and development in diagnostic tests for major lung diseases building on CyPath® Lung + AI foundation Global asthma therape…
Read attachment ↗ex4-1.htm · 8-K · 2026-10-09
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Issue Shares: Date: October 9, 2026 ────────────────────────────────────── THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “ Warrant ”) certifies that, for value received, [__] or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “ Initial Exercise …
Read attachment ↗ex4-2.htm · 8-K · 2026-10-09
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗